These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27258423)

  • 1. Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes.
    Vanderstichele HM; Janelidze S; Demeyer L; Coart E; Stoops E; Herbst V; Mauroo K; Brix B; Hansson O
    J Alzheimers Dis; 2016 May; 53(3):1121-32. PubMed ID: 27258423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40).
    Vanderstichele H; Demeyer L; Janelidze S; Coart E; Stoops E; Mauroo K; Herbst V; François C; Hansson O
    Alzheimers Res Ther; 2017 Jun; 9(1):40. PubMed ID: 28587660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays.
    Schauer SP; Mylott WR; Yuan M; Jenkins RG; Rodney Mathews W; Honigberg LA; Wildsmith KR
    Alzheimers Res Ther; 2018 Nov; 10(1):118. PubMed ID: 30486870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of cerebrospinal fluid Aβ1-42 measurements: evaluation of pre-analytical factors using a novel Elecsys immunosassay.
    Rozga M; Bittner T; Höglund K; Blennow K
    Clin Chem Lab Med; 2017 Aug; 55(10):1545-1554. PubMed ID: 28160541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting.
    Gervaise-Henry C; Watfa G; Albuisson E; Kolodziej A; Dousset B; Olivier JL; Jonveaux TR; Malaplate-Armand C
    J Alzheimers Dis; 2017; 57(2):437-445. PubMed ID: 28269771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays.
    Lewczuk P; Lelental N; Spitzer P; Maler JM; Kornhuber J
    J Alzheimers Dis; 2015; 43(1):183-91. PubMed ID: 25079805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reference measurement procedure for CSF amyloid beta (Aβ)
    Pannee J; Portelius E; Minthon L; Gobom J; Andreasson U; Zetterberg H; Hansson O; Blennow K
    J Neurochem; 2016 Nov; 139(4):651-658. PubMed ID: 27579672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ
    Willemse E; van Uffelen K; Brix B; Engelborghs S; Vanderstichele H; Teunissen C
    Alzheimers Dement; 2017 Aug; 13(8):885-892. PubMed ID: 28222302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with Aβ42 and influence of disease on the total-Aβ42/Aβ40 ratio.
    Slemmon JR; Shapiro A; Mercken M; Streffer J; Romano G; Andreasen N; Zetterberg H; Blennow K
    J Neurochem; 2015 Dec; 135(5):1049-58. PubMed ID: 26332787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals.
    Berge G; Lauridsen C; Sando SB; Holder DJ; Møller I; Aasly JO; Bråthen G; Savage MJ; White LR
    J Alzheimers Dis; 2016; 49(2):493-502. PubMed ID: 26484901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Preanalytical Cerebrospinal Fluid Handling and Storage Factors on Measurement of Aβ1-42, Aβ1-40, and pTau181 Using an Automated Chemiluminescent Platform.
    Ho S; Darrow J; De Simone F; Calabro A; Gannon S; Esquivel R; Thakker P; Khingelova K; Rao A; Zhang Y; Moghekar A
    J Appl Lab Med; 2024 Jul; 9(4):789-802. PubMed ID: 38712812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides.
    Bibl M; Esselmann H; Otto M; Lewczuk P; Cepek L; Rüther E; Kornhuber J; Wiltfang J
    Electrophoresis; 2004 Sep; 25(17):2912-8. PubMed ID: 15349929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab.
    Lachno DR; Evert BA; Vanderstichele H; Robertson M; Demattos RB; Konrad RJ; Talbot JA; Racke MM; Dean RA
    J Alzheimers Dis; 2013; 34(4):897-910. PubMed ID: 23302661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
    Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
    J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation and Clinical Utility of ELISA Methods for Quantification of Amyloid-β of Peptides in Cerebrospinal Fluid Specimens from Alzheimer’s Disease Studies.
    Lachno DR; Evert BA; Maloney K; Willis BA; Talbot JA; Vandijck M; Dean RA
    J Alzheimers Dis; 2015; 45(2):527-42. PubMed ID: 25547638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiling amyloid-β peptides as biomarkers for cerebral amyloid angiopathy.
    van den Berg E; Kersten I; Brinkmalm G; Johansson K; de Kort AM; Klijn CJM; Schreuder FHBM; Gobom J; Stoops E; Portelius E; Gkanatsiou E; Zetterberg H; Blennow K; Kuiperij HB; Verbeek MM
    J Neurochem; 2024 Jul; 168(7):1254-1264. PubMed ID: 38362804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform.
    Delaby C; Muñoz L; Torres S; Nadal A; Le Bastard N; Lehmann S; Lleó A; Alcolea D
    Clin Chim Acta; 2019 Mar; 490():98-101. PubMed ID: 30579960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards a unified protocol for handling of CSF before β-amyloid measurements.
    Janelidze S; Stomrud E; Brix B; Hansson O
    Alzheimers Res Ther; 2019 Jul; 11(1):63. PubMed ID: 31324260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine.
    Chiasserini D; Biscetti L; Farotti L; Eusebi P; Salvadori N; Lisetti V; Baschieri F; Chipi E; Frattini G; Stoops E; Vanderstichele H; Calabresi P; Parnetti L
    J Alzheimers Dis; 2016 Jul; 54(1):55-67. PubMed ID: 27447425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.